Pfizer (PFE) Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has 18 years of Accumulated Expenses data on file, last reported at $2.7 billion in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.7 billion, up 4.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 4.14% YoY), and the FY2025 annual result was $3.6 billion, down 5.94% from the prior year.
• Accumulated Expenses eased to $2.7 billion in Q1 2026 per PFE's latest filing, from $3.6 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $3.8 billion in Q4 2024 and troughed at $2.0 billion in Q3 2023.
• A 5-year average of $2.7 billion and a median of $2.6 billion in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses retreated 18.52% in 2023, then surged 42.62% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $3.4 billion in 2022, then slipped by 18.52% to $2.8 billion in 2023, then surged by 38.26% to $3.8 billion in 2024, then declined by 5.94% to $3.6 billion in 2025, then declined by 24.79% to $2.7 billion in 2026.
• Business Quant data shows PFE's Accumulated Expenses at $2.7 billion in Q1 2026, $3.6 billion in Q4 2025, and $3.0 billion in Q3 2025.